Market Place
Sourcing Support
Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
30 Oct 2024 //
GLOBENEWSWIRE
Windtree Announces Publication Of Istaroxime Phase 2b Design
09 Oct 2024 //
GLOBENEWSWIRE
Windtree Reports Ph 2b Results For Istaroxime In Heart Failure
30 Sep 2024 //
GLOBENEWSWIRE
Windtree’s shock med raises blood pressure in latest phase 2 win
26 Sep 2024 //
BIOSPACE
Windtree Completes Enrollment For Istaroxime Study
04 Sep 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces License Agreement with Lee™s Pharmaceuticals
17 Jan 2024 //
GLOBENEWSWIRE
Windtree Announces Reduction In Arrythmias In A New Study With Istaroxime
02 Jan 2024 //
GLOBENEWSWIRE
Windtree Announces the Start of Patient Dosing In Phase 2 Study of Istaroxime
18 Dec 2023 //
GLOBENEWSWIRE
Windtree Therapeutics to Host Investor Day Focusing on Cardiogenic Shock Market
05 Jun 2023 //
GLOBENEWSWIRE
Windtree Announces Pub Its SEISMiC Pre Shock Study Comparing 2 dose Istaroxime
27 Apr 2023 //
GLOBENEWSWIRE
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care
06 Mar 2023 //
GLOBENEWSWIRE
Windtree Announces Issuance of Istaroxime Patent from U.S. Patent
24 Feb 2023 //
GLOBENEWSWIRE
Windtree Announces Notice of Allowance from the US Patent
25 Oct 2022 //
GLOBENEWSWIRE
Windtree Announces Istaroxime Late Breaker Abstract from its Positive Phase 2
26 Sep 2022 //
GLOBENEWSWIRE
WindTree has clinical results it wants, but in a bear market
30 Jun 2022 //
FIERCEBIOTECH
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results
29 Jun 2022 //
GLOBENEWSWIRE
Journey Medical Corp to Present at B. Riley Securities 22nd Annual Conference
23 May 2022 //
GLOBENEWSWIRE
Windtree Therapeutics Sees Positive Results for Istaroxime
21 Apr 2022 //
MARKETWATCH
Windtree Therapeutics receives new US patent for istaroxime administration
27 Oct 2021 //
PHARMABIZ
Windtree Announces Notice of Allowance from the US Patent and Trademark Office
25 Oct 2021 //
GLOBENEWSWIRE
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment
14 Oct 2021 //
GLOBENEWSWIRE
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO®
14 Oct 2021 //
GLOBENEWSWIRE
ScinoPharm and CVie Therapeutics Limited To Jointly Develop New Heart Failure Drug
05 Aug 2016 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.